CLAIMS

1. A composition comprising a fusion protein comprising an interferon antagonist and a targeting moiety, wherein:

   the interferon antagonist is a human IFNα2 comprising a mutation at position R120E ; and

   the targeting moiety consists of an antibody or an antibody-like molecule that provides cell-specific targeting of the antagonistic activity.

2. The composition according to claim 1, wherein said targeting moiety comprises a variable domain of camelid heavy chain antibody (VHH) or a variable domain of new antigen receptor (VNAR).

3. The composition according to any of the preceding claims, wherein said targeting moiety is specifically targeted to a marker of a cancer cell.

4. The composition according to any of the preceding claims, wherein said targeting moiety is specifically targeted to a marker of an immune cell.

5. The composition according to claim 1, wherein said targeting moiety is specifically targeted to leptin receptor.

6. The composition according to claim 1, wherein said targeting moiety is specifically targeted to CD20.

7. The composition according to claim 1, wherein the human IFNα2 comprises a second mutation that decreases binding activity of the interferon antagonist, wherein the second mutation is selected from R149A or L153A.

8. A composition comprising a fusion protein comprising an interferon antagonist and a targeting moiety, wherein:

   the interferon antagonist is human IFNα2 comprising R120E and L153A mutations, and

   the targeting moiety comprises a variable domain of camelid heavy chain antibody (VHH) or a variable domain of new antigen receptor (VNAR) specifically targeted to CD20.

9. A composition of claim 1 for use in treating an autoimmune disease, wherein the composition is to be administered to a subject in need thereof.

10. A composition of claim 8 for use in treating an autoimmune disease, wherein composition is to be administered to a subject in need thereof.

11. Use of a composition of claim 1 in the manufacture of a medicament for treating an autoimmune disease.

12. Use of a composition of claim 8 in the manufacture of a medicament for treating an autoimmune disease.